secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011585
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q2 net loss $0.42/shr; expects MAD Phase 1 topline for GT-02287 in August 2024
--------------------------------------------------------------------------------

- Net loss per share $0.42 for Q2 2024 vs $0.62 in Q2 2023; cash & securities $16.9M as of June 30, 2024.
- Topline results from MAD Phase 1 study of GT-02287 for Parkinson's disease expected in August 2024.
- Phase 1b study in Parkinson's patients with/without GBA1 mutation initiation anticipated in Q4 2024.
- Gene Mack appointed interim CEO and CFO; Khalid Islam serves as Executive Chairman.
- Completed underwritten public offering with approximately $10.0M net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024011585/0001558370-24-011585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024011585/ganx-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer